News

The Latest News from LGM Pharma

LGM Pharma Expands U.S. Manufacturing, Bringing Total Investment to $15M Across Texas and Colorado Sites
— $9M Second Phase of CDMO Investment Builds on 2025 $6M Expansion, Funding Facility Upgrades and Increased...
LGM Pharma Invests $6M in U.S. Drug Manufacturing Capabilities for Liquids, Suspensions, Semi-Solids, and Suppositories
LGM Pharma Invests $6M in U.S. Drug Manufacturing Capabilities for Liquids, Suspensions, Semi-Solids,...
N-Zyme Biomedical and LGM Pharma are Developing the World’s First Pepsin Inhibitor for Reflux Disease
N-Zyme Biomedical and LGM Pharma are Developing the World’s First Pepsin Inhibitor for Reflux Disease...
New Harbor Capital Portfolio Company LGM Pharma Promotes CFO and CCO
October 22, 2024 – Chicago, IL – New Harbor Capital (“New Harbor”) is excited to announce that portfolio...
LGM Pharma Expands Analytical Testing Services with New Endotoxin and Rapid Sterility Testing Capabilities
—New Capabilities and State-of-the-Art Equipment at Irvine Facility Accelerates Turnaround Time and Enhances...
New Harbor Capital Completes Recapitalization of Portfolio Company LGM Pharma to Support Its Continued Growth
Chicago, IL and Boca Raton, FL, New Harbor Capital (“New Harbor”) announced today the recapitalization,...
1 2 3